Search Results - Hamza Hashmi

Beyond BCMA: the next wave of CAR T cell therapy in multiple myeloma by Kevin Miller, Hamza Hashmi, Sridevi Rajeeve

Get full text

Primary Effusion Lymphoma without an Effusion: A Rare Case of Solid Extracavitary Variant of Primary Effusion Lymphoma in an HIV-Positive Patient by Hamza Hashmi, Drew Murray, Samer Al-Quran, William Tse

Get full text

A Rare Case of Erdheim-Chester Disease (Non-Langerhans Cell Histiocytosis) with Concurrent Langerhans Cell Histiocytosis: A Diagnostic and Therapeutic Challenge by Hamza Hashmi, Drew Murray, John Greenwell, Marwan Shaikh, Soumit Basu, Maxwell Krem

Get full text

“Fast but not so furious”: A condensed step‐up dosing schedule of teclistamab for relapsed/refractory multiple myeloma by Kevin C. Graf, James A Davis, Alyssa Cendagorta, Katelynn Granger, Kelly J. Gaffney, Kimberly Green, Brian T Hess, Hamza Hashmi

Get full text

A real-world experience of efficacy and safety of belantamab mafodotin in relapsed refractory multiple myeloma by Rachel Dileo, Prerna Mewawalla, Kalaivani Babu, Yue Yin, Christopher Strouse, Ethan Chen, Hira Shaikh, James A. Davis, Kimberly M. Green, Omar Alkharabsheh, Aliya Rashid, Bidushi Pokhrel, Nausheen Ahmed, Al-Ola Abdallah, Hamza Hashmi

Get full text

Impact of Extraosseous Extramedullary Disease on Outcomes of Patients with Relapsed-Refractory Multiple Myeloma receiving Standard-of-Care Chimeric Antigen Receptor T-Cell Therapy by Danai Dima, Al-Ola Abdallah, James A. Davis, Hussein Awada, Utkarsh Goel, Aliya Rashid, Shaun DeJarnette, Faiz Anwer, Leyla Shune, Shahzad Raza, Zahra Mahmoudjafari, Louis Williams, Beth Faiman, Joseph P. McGuirk, Craig S. Sauter, Nausheen Ahmed, Jack Khouri, Hamza Hashmi

Get full text

Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed refractory multiple myeloma by Tara Sebastian, Sridevi Rajeeve, Tasmin Farzana, Ross Firestone, Eric Jurgens, Kevin Miller, Bruno Almeida Costa, Alexander Lesokhin, Carlyn Rose Tan, Gunjan Shah, Neha Korde, Heather Landau, Michael Scordo, Hani Hassoun, Kylee Maclachlan, Urvi Shah, Malin Hultcrantz, Andriy Derkach, David Nemirovsky, Sergio Giralt, Saad Usmani, Sham Mailankody, Hamza Hashmi

Get full text

Correction: Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed refractory multiple myeloma by Tara Sebastian, Sridevi Rajeeve, Tasmin Farzana, Ross Firestone, Eric Jurgens, Kevin Miller, Bruno Almeida Costa, Alexander Lesokhin, Carlyn Rose Tan, Gunjan Shah, Neha Korde, Heather Landau, Michael Scordo, Hani Hassoun, Kylee Maclachlan, Urvi Shah, Malin Hultcrantz, Andriy Derkach, Derkach Nemirovsky, Sergio Giralt, Saad Usmani, Sham Mailankody, Hamza Hashmi

Get full text

A differentiated effector T cell repertoire defines a functionally high-risk group of smoldering myeloma patients by Ross S. Firestone, Anish K. Simhal, Theresia Akhlaghi, Jung Hun Oh, Devin McAvoy, Kylee H. Maclachlan, Juan-Jose Garces, Sham Mailankody, Hani Hassoun, Urvi A. Shah, Neha Korde, Carlyn R. Tan, Sridevi Rajeeve, Hamza Hashmi, Alexander M. Lesokhin, Kinga Hosszu, Francesco Maura, Joseph O. Deasy, Saad Z. Usmani, Malin Hultcrantz

Get full text

Talquetamab in heavily pretreated patients with multiple myeloma, including BCMA-refractory by Andrew J. Vegel, Bradley T. Loeffler, Jonathan Lochner, Reed Friend, Alma Habib, Marshall McKenna, Jordan Snyder, Kimberly Green, Rachel DiLeo, Gina Patrus, Prerna Mewawalla, Muhammad Umair Mushtaq, Christopher Strouse, Yun Kyoung Ryu Tiger, Nausheen Ahmed, Abdullah M. Khan, Hamza Hashmi, Barry Paul, Shebli Atrash, Al-Ola Abdallah, Hira Shaikh

Get full text

Outcomes in frail patients receiving BCMA-directed bispecific antibodies for relapsed/refractory multiple myeloma by Benjamin Adegbite, Carlyn Rose Tan, Tala Shekarkhand, Ross S. Firestone, Eric M. Jurgens, Kevin Miller, Alexander M. Lesokhin, Gunjan L. Shah, Neha Korde, Sridevi Rajeeve, Heather J. Landau, Michael Scordo, Hani Hassoun, Kylee H. Maclachlan, Urvi A. Shah, Malin Hultcrantz, Issam S. Hamadeh, Andriy Derkach, David Nemirovsky, Sergio A. Giralt, Sham Mailankody, Saad Z. Usmani, Hamza Hashmi

Get full text

Practical use of talquetamab in relapsed/refractory multiple myeloma: the Memorial Sloan Kettering Cancer Center experience by Bruno Almeida Costa, Carlyn Rose Tan, Tala Shekarkhand, Ross S. Firestone, Eric M. Jurgens, Kevin Miller, Alexander M. Lesokhin, Gunjan L. Shah, Neha Korde, Sridevi Rajeeve, Heather J. Landau, Michael Scordo, Hani Hassoun, Kylee H. Maclachlan, Urvi A. Shah, Malin Hultcrantz, Issam S. Hamadeh, Alice X. Wang, Sergio A. Giralt, Sham Mailankody, Saad Z. Usmani, Hamza Hashmi

Get full text

Restarting teclistamab and talquetamab after prolonged dose delay may not require re–step-up dosing by Carlyn Rose Tan, Alice Wang, David Nemirovsky, Andriy Derkach, Tala Shekarkhand, Issam Hamadeh, Kylee Maclachlan, Malin Hultcrantz, Hani Hassoun, Sham Mailankody, Alexander Lesokhin, Urvi A. Shah, Sridevi Rajeeve, Hamza Hashmi, Dhwani Patel, Ross Firestone, Eric Jurgens, Kevin Miller, Gunjan L. Shah, Michael Scordo, Heather J. Landau, Sergio A. Giralt, Neha Korde, Saad Z. Usmani

Get full text

Functionally high-risk disease is associated with poor outcomes after late-line CAR T-cell therapy for multiple myeloma by Hamza Hashmi, Tara Sebastian, Sridevi Rajeeve, Tasmin Farzana, Ross S. Firestone, Eric M. Jurgens, Kevin C. Miller, Francesco Maura, Alexander M. Lesokhin, Carlyn R. Tan, Gunjan L. Shah, Neha Korde, Heather J. Landau, Maximillian Merz, Michael Scordo, Hani Hassoun, Kylee H. Maclachlan, Urvi A. Shah, Malin L. Hultcrantz, Andriy Derkach, David Nemirovsky, Sergio Giralt, Sham Mailankody, Saad Z. Usmani

Get full text

Factors associated with refractoriness or early progression after idecabtagene vicleucel in patients with relapsed/ refractory multiple myeloma: US Myeloma Immunotherapy Consortium... by Hamza Hashmi, Doris K. Hansen, Lauren C. Peres, Omar Castaneda Puglianini, Ciara Freeman, Gabriel De Avila, Surbhi Sidana, Leyla Shune, Douglas W. Sborov, James Davis, Charlotte Wagner, Mehmet H. Kocoglu, Shebli Atrash, Peter Voorhees, Gary Simmons, Christopher Ferreri, Nilesh Kalariya, Larry D. Anderson Jr., Aimaz Afrough, Danai Dima, Jack Khouri, Joseph McGuirk, Fred Locke, Rachid Baz, Krina K. Patel, Melissa Alsina

Get full text

Safety and efficacy of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma: a CIBMTR study by Doris K. Hansen, Danai Dima, Hira Mian, Jakob Devos, Ruta Brazauskas, Temitope Oloyede, Aimaz Afrough, Nausheen Ahmed, Larry Anderson, Rahul Banerjee, Jesus G. Berdeja, Aram Bidikian, Binod Dhakal, Ajoy Dias, Yvonne Efebera, Muhammad Salman Faisal, Lohith Gowda, Hamza Hashmi, Abu-Sayeef Mirza, Meera Mohan, Ravi Narra, Ashley E. Rosko, Mark Schroeder, Taiga Nishihori, Heather Landau, Saad Usmani, Marcelo C. Pasquini, Othman S. Akhtar, Surbhi Sidana, Krina K. Patel

Get full text

Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel by Saurabh Zanwar, Surbhi Sidana, Leyla Shune, Omar Castaneda Puglianini, Oren Pasvolsky, Rebecca Gonzalez, Danai Dima, Aimaz Afrough, Gurbakhash Kaur, James A. Davis, Megan Herr, Hamza Hashmi, Peter Forsberg, Douglas Sborov, Larry D. Anderson Jr, Joseph P. McGuirk, Charlotte Wagner, Alex Lieberman-Cribbin, Adriana Rossi, Ciara L. Freeman, Frederick L. Locke, Shambavi Richard, Jack Khouri, Yi Lin, Krina K. Patel, Shaji K. Kumar, Doris K. Hansen

Get full text

Outcomes of patients with secondary central nervous system lymphoma following CAR T-cell therapy: a multicenter cohort study by Narendranath Epperla, Lei Feng, Nirav N. Shah, Lindsey Fitzgerald, Harsh Shah, Deborah M. Stephens, Catherine J. Lee, Thomas Ollila, Geoffrey Shouse, Alexey V. Danilov, Kevin A. David, Pallawi Torka, Hamza Hashmi, Brian Hess, Stefan K. Barta, Jason T. Romancik, Jonathon B. Cohen, Kaitlin Annunzio, Adam S. Kittai, John Reneau, Joanna Zurko, Imran A. Nizamuddin, Jane N. Winter, Leo I. Gordon, Shuo Ma, Romil Patel, Loretta Nastoupil, Sairah Ahmed, Reem Karmali

Get full text

Idecabtagene vicleucel chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma with renal impairment by Surbhi Sidana, Lauren C. Peres, Hamza Hashmi, Hitomi Hosoya, Christopher Ferreri, Jack Khouri, Danai Dima, Shebli Atrash, Peter Voorhees, Gary Simmons, Douglas W. Sborov, Nilesh Kalariya, Vanna Hovanky, Sushma Bharadwaj, David Miklos, Charlotte Wagner, Mehmet H. Kocoglu, Gurbakhash Kaur, James A. Davis, Shonali Midha, Murali Janakiram, Ciara Freeman, Melissa Alsina, Frederick Locke, Rebecca Gonzalez, Yi Lin, Joseph McGuirk, Aimaz Afrough, Leyla Shune, Krina K. Patel, Doris K. Hansen

Get full text

Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy by Christopher J. Ferreri, Michelle A. T. Hildebrandt, Hamza Hashmi, Leyla O. Shune, Joseph P. McGuirk, Douglas W. Sborov, Charlotte B. Wagner, M. Hakan Kocoglu, Aaron Rapoport, Shebli Atrash, Peter M. Voorhees, Jack Khouri, Danai Dima, Aimaz Afrough, Gurbakhash Kaur, Larry D. Anderson, Gary Simmons, James A. Davis, Nilesh Kalariya, Lauren C. Peres, Yi Lin, Murali Janakiram, Omar Nadeem, Melissa Alsina, Frederick L. Locke, Surbhi Sidana, Doris K. Hansen, Krina K. Patel, Omar Alexis Castaneda Puglianini

Get full text